Hybrigenics Appoints Dr Alain Munoz to its Board of Directors

Hybrigenics has announced the appointment of Dr Alain Munoz to its board as a non-executive independent director. Dr Munoz replaces Dr Bernhard Ehmer, president of ImClone Systems, and will chair the clinical advisory board.

Dr Munoz, cardiologist and anaesthesiologist by training, has over 20 years’ experience in the pharmaceutical industry at senior management level with the Sanofi Group as R&D vice-president (VP) and the French pharmaceutical company Fournier as VP of R&D and business development, subsequently becoming senior VP of the pharmaceutical division.

Under his leadership, numerous drug product registrations were obtained world-wide, generating significant sales (Adenocard®, Plavix®, Lipanthyl®/Tricor™, Esclim®).

He has an in-depth knowledge of the US and Japanese markets, and has concluded several major licensing deals with world-class partners in the industry.

He currently acts as an entrepreneur developing his own projects and an adviser to investors. He is a board member of several biotechnology companies (NYSE Euronext: Vivalis SA, VLS; Novagali Pharma SA, NOVA. Nasdaq OMX: Zealand Pharma A/S, ZEAL).

“I'm delighted to welcome Alain Munoz to the board of Hybrigenics. Alain brings scientific and clinical know how as well as competence in the management of a public French company, thereby complementing the existing competences of the company's board,” said Daan Ellens, chairman of Hybrigenics’ board of directors.

Ellens continued, “I’d like to warmly thank Bernhard Ehmer who has accompanied Hybrigenics’ clinical development from scratch in 2006 until the successful completion of Phase IIa of inecalcitol in castrate-resistant prostate cancer this year,” added Remi Delansorne, Hybrigenics’ CEO.